Overview

A Study of SKB264 in Combination with Osimertinib Versus Osimertinib in Patients with Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Status:
RECRUITING

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with osimertinib as first-Line treatment for patients with epidermal growth factor receptor (EGFR) mutations, locally advanced or metastatic non-squamous non-small cell lung cancer.

Phase:

PHASE3

Details

Lead Sponsor:

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Treatments:

osimertinib